Literature DB >> 3021055

In vitro and in vivo activities of phosphate derivatives of 9-(1,3-dihydroxy-2-propoxymethyl)-guanine against cytomegaloviruses.

A E Duke, D F Smee, M Chernow, R Boehme, T R Matthews.   

Abstract

The anti-cytomegalovirus activities of four phosphate derivatives of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) were evaluated against human, monkey and murine viruses. The 5'-mono-, 3'5'-bis(mono-), and 3',5'-cyclic monophosphate and 5'-homophosphonate forms of DHPG inhibited virus plaque formation at 1-15 microM. The cyclic phosphate and homophosphonate were more active than the other compounds against murine cytomegalovirus (MCMV) in vitro. In an in vivo MCMV infection model, DHPG homophosphonate and DHPG were equally effective at reducing mortality at greater than or equal to 10 mg/kg. The cyclic phosphate was active at 10-20 mg/kg but toxic at greater than or equal to 40 mg/kg. The phosphorylation of DHPG phosphate and DHPG phosphonate, as well as the inhibition of human cytomegalovirus DNA polymerase by their respective triphosphates, were also examined.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021055     DOI: 10.1016/0166-3542(86)90025-2

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

1.  Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient mice.

Authors:  D F Smee; S T Sugiyama; E J Reist
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 2.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

3.  Evaluation of continuous cell lines in antiviral studies with murine cytomegalovirus.

Authors:  D F Smee; A Colletti; H A Alaghamandan; L B Allen
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

4.  Effect of 2'-nor-cyclic GMP against guinea pig cytomegalovirus infection.

Authors:  Z H Yang; H L Lucia; R L Tolman; R J Colonno; G D Hsiung
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  Potent anti-murine cytomegalovirus activity and reduced nephrotoxicity of ganciclovir cyclic phosphonate.

Authors:  D F Smee; E J Reist
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

6.  A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives.

Authors:  V Sullivan; K K Biron; C Talarico; S C Stanat; M Davis; L M Pozzi; D M Coen
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

Review 7.  Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.

Authors:  Nancy Perrottet; Laurent A Decosterd; Pascal Meylan; Manuel Pascual; Jerome Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.